Immunotherapeutics for Autoimmune Encephalopathies and Dementias

被引:0
|
作者
Andrew McKeon
机构
[1] Mayo Clinic,College of Medicine
来源
关键词
Autoimmune; Autoimmune encephalopathies; Immunotherapeutics; Encephalopathy; Dementia; Paraneoplastic, Immunotherapy; Steroids; Plasma exchange; Intravenous immune globulin; IVIg; Rituximab; Cyclophosphamide; Azathioprine; Mycophenolate mofetil;
D O I
暂无
中图分类号
学科分类号
摘要
The timely implementation of immunotherapy is key to successful treatment of autoimmune encephalopathies or dementias (from here on will be referred to as autoimmune encephalopathies). There are different levels of diagnostic certainty which should guide the immunological treatment of autoimmune encephalopathies. There is a high level of diagnostic certainty for patients who have classic limbic encephalitis and have a neural antibody detected in serum or CSF (such as potassium channel complex antibody). For these patients, initiating high-dose corticosteroids or IVIg is indicated, with plasma exchange, rituximab or cyclophosphamide used as second-line therapy if first-line therapy proves only partially beneficial. There is a lower level of diagnostic certainty in patients with non-limbic atypical phenotypes (though rapidly progressive) when no neural antibody is detected in serum and CSF. A trial of corticosteroids or IVIg (or both sequentially) may be undertaken in these patients, but if no objective improvements occur, further immunotherapy is unlikely to be beneficial. Antiepileptic treatment also plays a critical role in those who have seizures as well as cognitive symptoms. Evaluation for and treatment of any underlying cancer is another component for those patients with a paraneoplastic cause of encephalitis. An individualized maintenance regimen needs to be designed for patients who do improve with immunotherapy. Individual factors that need to be considered when formulating a program of maintenance treatment include disease severity, antibody specificity and proclivity for disease relapse. Azathioprine and mycophenolate mofetil are frequently used for the purpose of remission maintenance, and should permit gradual withdrawal of steroids, IVIg or more toxic immunosuppressants. The duration of maintenance therapy is uncertain, but this author typically recommends 3–5 years of relapse-free maintenance treatment before discontinuing immunotherapy altogether.
引用
收藏
页码:723 / 737
页数:14
相关论文
共 50 条
  • [41] Immunotherapeutics for nosocomial infections
    Patti, JM
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (06) : 673 - 679
  • [42] Corixa: Integrating immunotherapeutics
    Frederickson, RM
    MOLECULAR THERAPY, 2003, 7 (04) : 431 - 431
  • [43] Neonatal encephalopathies - Time to reconsider the cause of encephalopathies
    Edwards, AD
    Nelson, KB
    BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7172): : 1537 - 1538
  • [44] Editorial: Complement and Immunotherapeutics
    Okroj, Marcin
    Volokhina, Elena
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [45] Novel Immunotherapeutics on the Horizon
    de la Horie, Guy-Charles Fanneau
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2010, 30 (11): : 50 - 51
  • [46] Nanobody activation immunotherapeutics
    McNaughton, Brian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [47] Fungal Vaccines and Immunotherapeutics
    Santos, Evelyn
    Levitz, Stuart M.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2014, 4 (11):
  • [48] Immunotherapeutics for breast cancer
    Criscitiello, Carmen
    Curigliano, Giuseppe
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (06) : 602 - 608
  • [49] Biologics or immunotherapeutics for asthma?
    Tay, Hock L.
    Foster, Paul S.
    PHARMACOLOGICAL RESEARCH, 2020, 158
  • [50] Homophilic antibodies as immunotherapeutics
    Kohler, Heinz
    IMMUNOTHERAPY, 2013, 5 (03) : 235 - 246